Vaxart, Inc. (VXRT) stock

VXRTOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 10/30

$0.48+0.02 (+5.04%)

Close on Oct 19, 2026Market cap $115.61MP/E 4.0Yield –

Vaxart total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

Vaxart's total debt was $1.94M at Dec 31, 2018. For fiscal 2018 it was $1.94M, up 548.0% from the year before.

Period	Period end	Value	Change
FY2018	Dec 31, 2018	$1.94M	+548.0%
FY2016	Jun 30, 2016	$300.00K	-62.5%
FY2015	Jun 30, 2015	$800.00K	–

Change is against the same quarter a year earlier.

Periods

Period	Period end	Value	Change
Q4 FY2018CQ4 2018	Dec 31, 2018	$1.94M	+548.0%
Q3 FY2018CQ3 2018	Sep 30, 2018	$2.32M	+364.2%
Q2 FY2018CQ2 2018	Jun 30, 2018	$2.70M	+285.1%
Q4 FY2016CQ2 2016	Jun 30, 2016	$300.00K	-62.5%
Q3 FY2016CQ1 2016	Mar 31, 2016	$300.00K	–
Q2 FY2016CQ4 2015	Dec 31, 2015	$500.00K	–
Q1 FY2016CQ3 2015	Sep 30, 2015	$700.00K	–
Q4 FY2015CQ2 2015	Jun 30, 2015	$800.00K	–